Global /Australia /Healthcare /Biotechnology /BIT

Biotron Ltd.

BIT

• ASX: BIT • Delayed

0.0020AUD -20%

0.0014 USD

As of 14 June 2026, Biotron Ltd. has a market cap of $4.75M USD, ranking #44684 globally and #1583 in Australia. It ranks #3957 in the Healthcare sector, and #780 in the Biotechnology industry.

Global Rank

44684

Country Rank

1583

Sector Rank

3957

Industry Rank

780

Key Stats

Market Cap

$4.75MUSD

6.75M AUD

Enterprise Value

$3.6MUSD

5.11M AUD

Revenue (TTM)

-$610.00USD

-868.00 AUD

EBITDA (TTM)

-$1.39MUSD

-1.97M AUD

Net Income (TTM)

-$1.36MUSD

-1.94M AUD

PS Ratio

-7781.9

PB Ratio

2.5

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

CEO

Michelle Miller open_in_new

Employees

Founded

1999

Website

biotron.com.au open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-20%	-20%	-20%	-50%	-50%	-33%	-33%	-93%	-97%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	BIT Biotron Ltd ISIN: AU000000BIT4 Shares Out.: Shares Outstanding: 2.702B¹ Shares Float: 2.656B² TV: TradingView: ASX: BIT SA: Stock Analysis: ASX: BIT YF: Yahoo Finance: BIT.AX GF: Google Finance: ASX: BIT BA: Barron's: BIT MS: Morningstar: XASX: BIT	0.0020 AUD	TV: TradingView: ASX: BIT SA: Stock Analysis: ASX: BIT YF: Yahoo Finance: BIT.AX GF: Google Finance: ASX: BIT BA: Barron's: BIT MS: Morningstar: XASX: BIT
OTC Markets (OTCMKTS / OTC) MIC: OTCM	BITRF Biotron Ltd ISIN: AU000000BIT4 Shares Out.: Shares Outstanding: 1.327B¹ Shares Float: 1.31B² TV: TradingView: OTC: BITRF SA: Stock Analysis: OTC: BITRF YF: Yahoo Finance: BITRF GF: Google Finance: OTCMKTS: BITRF BA: Barron's: BITRF MS: Morningstar: PINX: BITRF	0.0100 USD	TV: TradingView: OTC: BITRF SA: Stock Analysis: OTC: BITRF YF: Yahoo Finance: BITRF GF: Google Finance: OTCMKTS: BITRF BA: Barron's: BITRF MS: Morningstar: PINX: BITRF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Biotron Ltd.

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 892K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.58B 5.09B AUD 75K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.02B 2.88B AUD 42K%	-	Australia
PolyNovo Ltd. ASX: PNV	$490.46M 697.75M AUD 10K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 3K%	-	Australia
Immutep Ltd. ASX: IMM	$65.26M 92.84M AUD 1K%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 4M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 3M%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 1M%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 944K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 891K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 592K%	43.8	South Korea

chevron_leftBack